This has been confirmed in human studies in breast cancer, where SPARC has been shown to cause the AKT-mediated phosphorylation of the MDM2 gene product, and subsequently the negative regulation of the tumour suppressor p53 [22]. This evidence concerns the gene SPARC and breast carcinoma.